Your browser doesn't support javascript.
loading
Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao, Lidong; Li, Yan; He, Peng; Chen, Zhen; Yang, Huaiyu; Li, Fangjun; Zhang, Siyuan; Wang, Danni; Wang, Guangyan; Yang, Shilong; Gong, Lihui; Ding, Fan; Ling, Mengyu; Wang, Xilu; Ci, Leilei; Dai, Lianpan; Gao, George Fu; Huang, Tao; Hu, Zhongyu; Ying, Zhifang; Sun, Jiufeng; Zuo, Xiaohu.
Afiliação
  • Gao L; Hunan Provincial Center for Disease Control and Prevention, Changsha, China.
  • Li Y; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
  • He P; National Institute for Food and Drug Control, Beijing, China.
  • Chen Z; National Institute for Food and Drug Control, Beijing, China.
  • Yang H; Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.
  • Li F; Hunan Provincial Center for Disease Control and Prevention, Changsha, China.
  • Zhang S; Hunan Provincial Center for Disease Control and Prevention, Changsha, China.
  • Wang D; Xiangtan Center for Disease Control and Prevention, Xiangtan, China.
  • Wang G; Xiangtan Center for Disease Control and Prevention, Xiangtan, China.
  • Yang S; Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.
  • Gong L; Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.
  • Ding F; Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.
  • Ling M; Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.
  • Wang X; Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.
  • Ci L; Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.
  • Dai L; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
  • Gao GF; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
  • Huang T; Hunan Provincial Center for Disease Control and Prevention, Changsha, China.
  • Hu Z; National Institute for Food and Drug Control, Beijing, China.
  • Ying Z; National Institute for Food and Drug Control, Beijing, China.
  • Sun J; Guangdong Provincial Institute of Public Health, Guangzhou, China.
  • Zuo X; Anhui Zhifei Longcom Biopharmaceutical, Hefei, China. Electronic address: zuoxiaohu@zhifeishengwu.com.
Lancet Child Adolesc Health ; 7(4): 269-279, 2023 04.
Article em En | MEDLINE | ID: mdl-36803632
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials / Guideline Limite: Adolescent / Adult / Child / Humans Idioma: En Revista: Lancet Child Adolesc Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials / Guideline Limite: Adolescent / Adult / Child / Humans Idioma: En Revista: Lancet Child Adolesc Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China